Glaukos (NYSE:GKOS) Stock Falls 10.6% – Here’s Why

Glaukos Corporation (NYSE:GKOS) traded down 10.6% during trading on Thursday. The company traded as low as $161.00 and last traded at $153.8550. 174,643 shares were traded during trading, a decline of 80% from the average session volume of 855,618 shares. The stock had previously closed at $172.18.

More Glaukos News

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: iDose TR delivered positive Phase 4 results. Glaukos said its sustained-release glaucoma therapy met the primary endpoint when used with cataract surgery, producing superior eye-pressure reduction versus cataract surgery alone in patients with open-angle glaucoma. The data could support broader adoption of iDose TR and strengthen the company’s commercial glaucoma pipeline. Glaukos Announces Positive Topline Results from Phase 4 Trial
• Positive Sentiment: Three-year Epioxa data showed durable benefits in keratoconus. The Phase 3 extension reported sustained efficacy and a favorable safety profile after a single treatment, supporting the long-term clinical value of Glaukos’ corneal portfolio and potentially improving the therapy’s commercial outlook. Glaukos Announces Positive Three-Year Epioxa Results
• Positive Sentiment: Glaukos expanded its retinal pipeline through an exclusive RevOpsis agreement. The deal covers RO-104, described as a first-in-class tri-specific biologic, along with exclusive rights to the RevMod platform. The agreement adds longer-term retinal growth potential, although the assets remain development-stage programs. Glaukos and RevOpsis Exclusive License Agreement
• Neutral Sentiment: Investor reaction was mixed. Despite the favorable iDose TR and Epioxa updates, market coverage indicated that GKOS shares declined, suggesting investors may be focused on valuation, execution risk, and the financial terms or development costs associated with expanding the retinal pipeline. Glaukos Expands Retina Pipeline
• Negative Sentiment: Insider selling added pressure. Reports said insider sales overshadowed the positive clinical news, potentially raising concerns about management’s confidence or prompting short-term profit-taking after GKOS’s strong longer-term performance. Glaukos Stock Slips on Insider Selling

Analyst Ratings Changes

Several analysts have recently commented on GKOS shares. Truist Financial increased their target price on Glaukos from $180.00 to $215.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. UBS Group began coverage on shares of Glaukos in a research report on Tuesday, July 28th. They set a “neutral” rating and a $150.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a report on Friday, July 17th. Jefferies Financial Group raised their price objective on shares of Glaukos from $190.00 to $210.00 and gave the company a “buy” rating in a research report on Tuesday, September 22nd. Finally, BTIG Research boosted their target price on shares of Glaukos from $193.00 to $202.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $180.54.

Glaukos Price Performance

The firm has a market capitalization of $9.75 billion, a price-to-earnings ratio of -50.88 and a beta of 0.69. The company has a quick ratio of 4.46, a current ratio of 5.04 and a debt-to-equity ratio of 0.10. The company’s fifty day moving average is $172.97 and its two-hundred day moving average is $145.88.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.07. The company had revenue of $185.61 million during the quarter, compared to analysts’ expectations of $150.93 million. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The business’s revenue for the quarter was up 49.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.24) EPS. Equities research analysts anticipate that Glaukos Corporation will post -0.32 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Glaukos news, COO Joseph Gilliam sold 60,000 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total transaction of $10,784,400.00. Following the transaction, the chief operating officer owned 72,588 shares in the company, valued at approximately $13,046,967.12. This trade represents a 45.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Alex R. Thurman sold 20,000 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $180.13, for a total value of $3,602,600.00. Following the transaction, the chief financial officer owned 43,906 shares of the company’s stock, valued at $7,908,787.78. The trade was a 31.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 93,025 shares of company stock worth $16,550,006. Company insiders own 5.90% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC increased its stake in Glaukos by 44.4% in the third quarter. GAMMA Investing LLC now owns 4,569 shares of the medical instruments supplier’s stock valued at $750,000 after purchasing an additional 1,404 shares in the last quarter. Farther Finance Advisors LLC raised its stake in Glaukos by 25.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 681 shares of the medical instruments supplier’s stock worth $112,000 after buying an additional 138 shares during the period. CoreCap Advisors LLC acquired a new stake in Glaukos during the 3rd quarter worth $33,000. Sequoia Financial Advisors LLC lifted its holdings in Glaukos by 11.3% during the second quarter. Sequoia Financial Advisors LLC now owns 2,311 shares of the medical instruments supplier’s stock worth $323,000 after acquiring an additional 234 shares in the last quarter. Finally, Integrated Wealth Concepts LLC bought a new position in Glaukos during the second quarter worth about $253,000. Institutional investors own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation is an ophthalmic medical technology company focused on developing and commercializing products intended to preserve and restore vision. The company’s primary business is minimally invasive glaucoma surgery (MIGS), which is designed to reduce intraocular pressure and potentially lessen patients’ dependence on glaucoma medications.

Glaukos’ glaucoma portfolio includes the iStent, iStent inject and iStent infinite systems, which are used in procedures to improve the eye’s natural fluid outflow.